penumbra stock: Company, Financials & Market Data

Penumbra (stock)

Penumbra stock refers to the publicly traded equity of Penumbra, Inc. (ticker: PEN), a United States–based medical device company known for interventional systems for neurovascular and peripheral vascular care. This article provides a comprehensive, neutral overview of Penumbra as a business and a stock-market listing: company profile, corporate history, products and operations, clinical and regulatory context, historical and recent financial performance, stock market information and trading metrics, ownership and analyst coverage, corporate governance, material events, investment risks, peer comparisons, and practical investor resources. Readers will learn where to find up-to-date quantitative metrics for penumbra stock and which resources to use for filings, earnings, and market data.

As of June 30, 2024, according to Nasdaq and Penumbra's investor relations materials, Penumbra, Inc. trades on the New York Stock Exchange under the ticker PEN. Investors and researchers should confirm the latest metrics (market capitalization, volume, 52-week range and other statistics) directly from official filings and market-data providers because market values change continuously.

Company overview

Penumbra, Inc. is a medical technology company that develops, manufactures and sells devices for acute and chronic vascular conditions. The firm's commercial focus centers on aspiration-based thrombectomy systems and related devices used in neurovascular applications (such as ischemic stroke treatment) and peripheral vascular interventions. Penumbra serves hospitals, interventional radiology and neurosurgery departments, and healthcare providers worldwide.

The company operates research, development and manufacturing functions to support its product portfolio, and it markets devices through a combination of direct sales teams and distribution partnerships in select international markets. Penumbra's organizational mission emphasizes improving patient outcomes through procedural efficiency and device innovation.

penumbra stock is commonly referenced by investors tracking the medical device and neurovascular subsector; the company is categorized within health-care equipment and supplies in market data providers.

Corporate history

Penumbra began as a privately held medical-device venture focused on devices for thrombectomy and aspiration therapies. Over time the company expanded its product lines and geographic reach through organic R&D, clinical collaborations and targeted commercial expansion. Major milestones typically cited in public disclosures include early regulatory clearances for flagship systems, expansion into peripheral vascular and surgical markets, and the build-out of manufacturing capability to support commercial scale.

The company completed an initial public offering and became a listed public company under the ticker PEN on the New York Stock Exchange. Since listing, Penumbra has pursued growth through both internal product development and selective acquisitions or licensing agreements that broadened its clinical footprint. Public filings and press releases chronicle these corporate steps, including the timing of product launches and strategic partnerships.

Key corporate history items investors track include:

• Product approvals and launches that expanded clinical indications.
• Entry into major international markets through regulatory clearances or distributors.
• Any acquisitions or strategic transactions that added complementary technologies or geographic reach.
• The company’s evolution from private to public status and continuing investor communications via filings.

Products and operations

Penumbra's product portfolio centers on aspiration and thrombectomy technologies for neurovascular and peripheral vascular interventions. Principal product categories include:

• Neurovascular thrombectomy systems and aspiration catheters designed to remove blood clots in acute ischemic stroke procedures.
• Aspiration pumps and accessory systems that provide procedural workflow support for aspiration-based therapies.
• Peripheral vascular devices and delivery systems for use in peripheral arterial disease and other non-cerebral vascular interventions.
• Supporting disposables, guide catheters and device-specific consumables required for procedures.

Research and development is a continuous focus; Penumbra often cites product iteration that balances clinician feedback, clinical evidence, and manufacturing efficiency. Manufacturing is typically conducted in regulated facilities compliant with medical device quality systems, and distribution combines direct sales in key markets with authorized distributors in other territories.

Clinical applications for Penumbra’s devices include emergency stroke thrombectomy, treatment of peripheral emboli, and other interventional procedures where aspiration removal of occlusive material is indicated. Hospitals and acute-care providers adopt these devices where clinical teams have established workflows for endovascular procedures.

Clinical trials, regulatory approvals and safety

Clinical evidence and regulatory clearances are central to adoption in interventional medicine. Penumbra and independent investigators have published outcome data and trial results relevant to its thrombectomy and aspiration systems. Major device approvals—such as clearances or approvals from the U.S. Food and Drug Administration (FDA) or equivalent regulators in other jurisdictions—are material events cited in investor communications.

Public safety considerations for medical-device companies include device performance, adverse-event reporting, and any recalls or field safety notices. Penumbra’s regulatory and safety profile is documented in its public filings and regulatory databases; investors review those records to assess product-related risks. Where the company has issued voluntary field corrections or received regulatory notices, these are typically described in company releases and regulatory filings.

Financial performance

The financial section summarizes historical revenue and profitability trends, cash flows, and other key metrics investors monitor when researching penumbra stock. Readers should consult the company’s SEC filings (10-K for annual results and 10-Q for quarterly results) for audited financial statements, management discussion and analysis (MD&A), and detailed notes.

Historical financials

Annual and quarterly revenue and net-income trends for Penumbra are traceable through SEC filings and public earnings releases. Historical financial tables show revenue growth driven by product sales, with margins and profitability influenced by product mix, R&D spending and operating costs. Macrotrends and major financial-data providers compile historical time series for revenue, net income, and key balance-sheet items.

Recent quarterly results

Recent earnings releases contain three primary investor takeaways: top-line revenue performance compared to guidance, operating profit or loss and adjusted metrics, and forward-looking commentary from management on demand, supply constraints, or new-product contributions. Investors typically compare reported results to consensus analyst expectations and review management’s guidance for the coming quarters.

Key financial ratios

Common ratios used to evaluate penumbra stock include:

• Price-to-earnings (P/E) ratio (when the stock is profitable on a trailing or forward basis).
• Price-to-sales (P/S) ratio, often used for growth-stage medtech companies.
• Gross margin, to monitor product profitability.
• Operating margin and adjusted EBITDA, for operational performance.
• Debt-to-equity and leverage ratios, to assess balance-sheet strength.

Analysts and investors also review cash flow from operations and free cash flow trends to assess capital flexibility and the ability to fund R&D and manufacturing investments.

Stock market information

Penumbra's stock market listing and trading data is the operational heart of penumbra stock research. The company is listed on the New York Stock Exchange under the ticker symbol PEN; trading and regulatory settlement occur in U.S. dollars. Market-data platforms and regulatory filings report share counts, float, market capitalization, historical price data and trading volumes.

Price history and performance

Price history for penumbra stock can be analyzed on multiple time horizons: intraday, monthly, year-to-date, and multi-year charts. Investors consider price-only returns as well as total returns (which account for dividends and corporate actions). Notable price moves are often associated with earnings releases, regulatory decisions, or clinical-trial readouts.

When reviewing price charts, investors typically look at trend patterns, support and resistance levels, and relative performance versus relevant indices or sector peers.

Trading statistics

Key trading statistics for penumbra stock that market participants monitor include typical daily trading volume (average daily volume), shares outstanding, free float (shares available for public trading), and liquidity measures such as bid-ask spreads. These metrics affect transaction costs and the ease with which large positions can be entered or exited.

Dividends and share actions

Historically, many growth-oriented medical-device firms reinvest earnings into R&D and expansion rather than paying cash dividends. Investors should check whether Penumbra pays dividends, and should review any historical stock splits, reverse splits or share-repurchase programs disclosed in company filings. Corporate actions can materially change per-share metrics and shareholder value calculations.

Ownership and analyst coverage

Institutional ownership and insider holdings are disclosed in periodic regulatory filings. Major institutional shareholders—mutual funds, pension funds and exchange-traded funds—are often listed in the company’s proxy statements and in third-party ownership summaries. Insiders (executives and directors) must file reports for purchases and sales; these filings provide insight into insider activity but are one of many data points investors consider.

Sell-side analyst coverage typically provides consensus revenue and earnings estimates, ratings and price targets. Investors can find aggregate analyst sentiment and the number of covering analysts on financial-data platforms and in company reports summarizing coverage trends.

Corporate governance and management

Penumbra’s governance framework includes a board of directors and executive leadership team (CEO, CFO and other senior officers). Disclosures in proxy statements and Form 10-K filings describe board structure, committee composition (audit, compensation, nominating), executive compensation, governance policies and codes of conduct.

Investor relations materials provide biographies of senior management and board members, and they summarize governance practices. For governance-minded investors, topics of interest include board independence, succession planning and executive incentive structures aligned to long-term shareholder value creation.

Major events and developments

Major, market-moving events for penumbra stock typically include the following categories:

• Quarterly earnings releases and management guidance updates.
• Regulatory approvals or clearances for new indications or devices.
• Clinical-trial readouts that confirm or challenge expected performance.
• Significant contracts with hospital systems or group purchasing organizations.
• Strategic acquisitions, licensing deals or partnerships that materially expand product sets or addressable markets.
• Notifications of product recalls or safety communications.

As of June 30, 2024, according to company investor communications and Nasdaq reporting, recent events cited by Penumbra included product introductions and ongoing clinical-evidence initiatives. Investors should consult the company’s press releases and SEC filings for precise dates and full disclosures of such events.

Risks and controversies

Investing in penumbra stock exposes investors to company-specific and industry-wide risks. Major categories include:

• Regulatory and clinical risk: Devices require regulatory clearances and approvals. Negative trial outcomes, adverse-event reports or regulatory actions can limit adoption or require costly corrective measures.
• Product liability and litigation: Medical-device firms may face lawsuits alleging device-related harm or manufacturing defects. Legal proceedings can result in damages, settlements or reputational impacts.
• Competition: The neurovascular and peripheral vascular device sectors include multiple established and emerging competitors. Competitive pressure can impact pricing, market share and R&D priorities.
• Reimbursement and healthcare policy: Reimbursement rules and hospital purchasing behavior influence device adoption. Changes in policy or payer coverage can affect procedure volumes.
• Market and financial risk: As a public company, Penumbra’s share price can be sensitive to broader equity-market volatility, interest-rate moves and investor sentiment toward growth stocks.

Investors should read the company’s risk factors included in SEC filings for a comprehensive and legally reviewed summary of identified risks.

Comparison with peers

Penumbra is typically benchmarked against other public and private firms in the medtech and neurovascular device space. Comparable metrics often include revenue growth, gross margin, R&D intensity, and clinical evidence supporting product differentiation. Peer comparisons can help investors assess relative valuation, market opportunity and product positioning.

When conducting peer analysis, investors commonly create peer sets that include companies with overlapping product portfolios or clinical end markets, and they review multiples such as EV/revenue and EV/EBITDA for valuation context.

Investor resources

Primary resources for researching penumbra stock include:

• Penumbra’s official investor relations materials and press-release archive — for corporate presentations, earnings releases and governance documents.
• SEC filings (Forms 10-K, 10-Q, 8-K and proxy statements) — for audited financial statements, risk disclosures and material-event reporting.
• Market-data providers and financial news outlets for up-to-date price data, trading volume, market capitalization and analyst consensus.
• Earnings call transcripts and investor presentations for management commentary on business trends.

For investors seeking a trusted place to trade or monitor their holdings, Bitget provides market access and trading tools. For custody or self-custody of digital assets associated with broader portfolios, Bitget Wallet is the recommended wallet option in this guide.

Note: This article does not provide investment advice. Always verify current statistics and consult qualified professional advisors when making financial decisions.

See also

• Medical device industry overview
• Thrombectomy and endovascular therapy
• Publicly traded medical device companies and sector indices

References

• Company investor relations materials and press releases (see Penumbra investor relations and SEC filings for official disclosures).
• Market-data providers and news outlets including Nasdaq, Macrotrends, Reuters, CNBC, Robinhood, CNN and Zacks for financial metrics, analyst coverage and market commentary.
• Clinical and regulatory databases for device clearances and safety notices.

As of June 30, 2024, according to Nasdaq and company filings, the company’s listing under ticker PEN and its public disclosures described in this article were current; readers should consult those sources for changes after that date.

External links

• Penumbra investor relations (company website and investor materials)
• SEC EDGAR (filings such as Form 10-K, 10-Q, and 8-K)
• Market data pages for PEN (stock quote, historical price and trading volume)

Further reading and next steps: Explore the company’s latest Form 10-Q and the most recent earnings call transcript to verify up-to-date financial results and management commentary. To trade or monitor penumbra stock, consider using Bitget’s trading platform and Bitget Wallet for integrated asset management.